MoneyWorks4Me

Bacil Pharma - Quaterly Results

11 Feb 2023 Evaluate
Revenue reduced marginally to stand at Rs. 0.00 millions during the quarter ended December 2022. The figure stood at Rs. 0.00 millions during the year-ago period.The Net Loss for the quarter ended December 2022 is Rs. -0.45 millions as compared to Net Loss of Rs. -0.22 millions of corresponding quarter ended December 2021 Operating profit Margin for the quarter ended December 2022 further decreased to -0.44% as compared to -0.21% of corresponding quarter ended December 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Income 0.02 0.16 -87.50 1.06 0.39 171.79 0.58 0.74 -21.62
PBIDT -0.44 -0.21 109.52 -0.25 -1.21 -79.34 -38.56 -2.34 1547.86
Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PBDT -0.44 -0.21 109.52 -0.25 -1.21 -79.34 -38.56 -2.34 1547.86
Depreciation 0.01 0.01 0.00 0.03 0.03 0.00 0.04 0.05 -20.00
PBT -0.45 -0.22 104.55 -0.28 -1.24 -77.42 -38.60 -2.39 1515.06
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -0.45 -0.22 104.55 -0.28 -1.24 -77.42 -38.60 -2.39 1515.06
Equity 58.90 58.90 0.00 58.90 58.90 0.00 58.90 58.90 0.00
PBIDTM(%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Peers
Company Name CMP
Sun Pharma. Inds. 1820.00
Dr. Reddys Labs. 1236.00
Cipla 1350.00
Lupin 2042.00
Zydus Lifesciences 1163.35
View more..